Dividend Aristocrats are among Wall Street's most beloved stocks. Some companies pay dividends, fewer companies manage to ...

Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.

Abbott's $23B Exact Sciences deal adds short-term risk and earnings dilution. Click here to read what this means for ABT ...

In the rush to get at-home tests on the market, they were released with short shelf lives on their packaging. But some have ...

Abbott is buying Exact Sciences, the maker of tests designed to detect early cancers, in a $21 billion deal, a sign of ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

Abbott Laboratories $21 billion deal to acquire cancer test maker Exact Sciences could bolster the company’s diagnostic ...